{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:39:49Z","timestamp":1788115189532,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"am","delay-in-days":254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institutes of Health (NIH)\/National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI127173"],"award-info":[{"award-number":["AI127173"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health (NIH)\/National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI117927"],"award-info":[{"award-number":["AI117927"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health (NIH)\/National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI115091"],"award-info":[{"award-number":["AI115091"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009342","name":"Aeras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministry of Economy and Competitiveness","doi-asserted-by":"publisher","award":["SAF2016-77433-R"],"award-info":[{"award-number":["SAF2016-77433-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.coi.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T15:00:16Z","timestamp":1523545216000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis"],"prefix":"10.1016","volume":"53","author":[{"given":"Jacqueline M","family":"Achkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Prados-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2018.04.004_bib0405","series-title":"Global tuberculosis report 2017","author":"WHO","year":"2017"},{"key":"10.1016\/j.coi.2018.04.004_bib0410","volume":"vol 2018","author":"WHO","year":"2018"},{"key":"10.1016\/j.coi.2018.04.004_bib0415","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0420","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coi.2017.07.008","article-title":"Tuberculosis vaccines\u2014perspectives from the NIH\/NIAID Mycobacteria vaccine testing program","volume":"47","author":"Izzo","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0425","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fimmu.2017.00556","article-title":"What we have learned and what we have missed in tuberculosis pathophysiology for a new vaccine design: searching for the \u201cpink swan\u201d","volume":"8","author":"Cardona","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0430","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in tuberculosis","volume":"27","author":"Cooper","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12271","article-title":"MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis","volume":"264","author":"Gold","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2018.04.004_bib0440","article-title":"Innate and adaptive cellular immune responses to Mycobacterium tuberculosis infection","volume":"5","author":"Mayer-Barber","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0445","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3389\/fimmu.2017.01755","article-title":"Strategies to improve vaccine efficacy against tuberculosis by targeting innate immunity","volume":"8","author":"Schaible","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0450","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.12276","article-title":"B cells and antibodies in the defense against Mycobacterium tuberculosis infection","volume":"264","author":"Achkar","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2018.04.004_bib0455","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.tube.2016.08.001","article-title":"Antibodies and tuberculosis","volume":"101","author":"Jacobs","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.coi.2018.04.004_bib0460","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20 years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0465","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2018.00121","article-title":"Next-generation vaccines based on Bacille Calmette\u2013Guerin","volume":"9","author":"Nieuwenhuizen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0470","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018523","article-title":"Novel vaccination strategies against tuberculosis","volume":"4","author":"Andersen","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0475","doi-asserted-by":"crossref","DOI":"10.1111\/resp.13245","article-title":"Tuberculosis vaccines: opportunities and challenges","author":"Zhu","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.coi.2018.04.004_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2018.04.004_sbref0485","doi-asserted-by":"crossref","first-page":"11290","DOI":"10.1038\/ncomms11290","article-title":"T-cell activation is an immune correlate of risk in BCG vaccinated infants","volume":"7","author":"Fletcher","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2018.04.004_bib0490","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMcibr1613268","article-title":"Antibodies to Mycobacterium tuberculosis","volume":"376","author":"Casadevall","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0495","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/IAI.73.10.6711-6720.2005","article-title":"Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies","volume":"73","author":"de Valliere","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_sbref0500","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/infdis\/jiw141","article-title":"Association of human antibodies to arabinomannan with enhanced mycobacterial opsonophagocytosis and intracellular growth reduction","volume":"214","author":"Chen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.04.004_sbref0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coi.2018.04.004_sbref0510","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.15252\/emmm.201606330","article-title":"Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis","volume":"8","author":"Zimmermann","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coi.2018.04.004_sbref0515","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1073\/pnas.1611776114","article-title":"Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_sbref0520","doi-asserted-by":"crossref","first-page":"e1006250","DOI":"10.1371\/journal.ppat.1006250","article-title":"Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine","volume":"13","author":"Prados-Rosales","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2018.04.004_bib0525","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.chom.2013.02.009","article-title":"Antibody-mediated immunity against tuberculosis: implications for vaccine development","volume":"13","author":"Achkar","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2018.04.004_bib0530","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CMR.11.3.514","article-title":"Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis","volume":"11","author":"Glatman-Freedman","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coi.2018.04.004_bib0535","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/infdis\/jis421","article-title":"Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients","volume":"206","author":"Kunnath-Velayudhan","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.04.004_bib0540","doi-asserted-by":"crossref","first-page":"14703","DOI":"10.1073\/pnas.1009080107","article-title":"Dynamic antibody responses to the Mycobacterium tuberculosis proteome","volume":"107","author":"Kunnath-Velayudhan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_bib0545","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1074\/mcp.M116.065953","article-title":"Identification of antibody targets for tuberculosis serology using high-density nucleic acid programmable protein arrays","volume":"16","author":"Song","year":"2017","journal-title":"Mol Cell Proteomics"},{"issue":"Suppl. 4","key":"10.1016\/j.coi.2018.04.004_bib0550","doi-asserted-by":"crossref","first-page":"S1179","DOI":"10.1093\/infdis\/jir451","article-title":"Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response","volume":"204","author":"Achkar","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.04.004_bib0555","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/CVI.00501-12","article-title":"Antibody responses to mycobacterial antigens in children with tuberculosis: challenges and potential diagnostic value","volume":"19","author":"Achkar","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0560","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nri.2017.69","article-title":"Heterogeneity in tuberculosis","volume":"17","author":"Cadena","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0565","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/IAI.01599-13","article-title":"Early changes by 18Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques","volume":"82","author":"Coleman","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)91001-3","article-title":"A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens","volume":"91","author":"Casadevall","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fcgamma receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2018.04.004_bib0580","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14760584.3.1.23","article-title":"Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens","volume":"3","author":"Igietseme","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2018.04.004_bib0585","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1074-7613(01)00139-X","article-title":"Intracellular antibody neutralizes Listeria growth","volume":"14","author":"Edelson","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2018.04.004_bib0590","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1172\/JCI38322","article-title":"Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism","volume":"120","author":"McClelland","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2018.04.004_sbref0595","doi-asserted-by":"crossref","first-page":"e1005687","DOI":"10.1371\/journal.ppat.1005687","article-title":"Patients with tuberculosis have a dysfunctional circulating B-cell compartment, which normalizes following successful treatment","volume":"12","author":"Joosten","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2018.04.004_sbref0600","doi-asserted-by":"crossref","first-page":"E5636","DOI":"10.1073\/pnas.1611987113","article-title":"CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection","volume":"113","author":"Foreman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_sbref0605","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1128\/IAI.00083-16","article-title":"Effects of B cell depletion on early Mycobacterium tuberculosis infection in cynomolgus macaques","volume":"84","author":"Phuah","year":"2016","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_bib0610","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/pmic.201100544","article-title":"Deciphering the proteome of the in vivo diagnostic reagent \u201cpurified protein derivative\u201d from Mycobacterium tuberculosis","volume":"12","author":"Cho","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.coi.2018.04.004_bib0615","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd3012","article-title":"Carbohydrate vaccines: developing sweet solutions to sticky situations?","volume":"9","author":"Astronomo","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coi.2018.04.004_bib0620","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1469-0691.2003.00530.x","article-title":"Carbohydrate\u2013protein conjugate vaccines","volume":"9","author":"Ada","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coi.2018.04.004_bib0625","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1054\/tuld.1998.0200","article-title":"The capsule of Mycobacterium tuberculosis and its implications for pathogenicity","volume":"79","author":"Daffe","year":"1999","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.coi.2018.04.004_bib0630","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1128\/IAI.72.10.5676-5686.2004","article-title":"The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages","volume":"72","author":"Stokes","year":"2004","journal-title":"Infect Immun"},{"issue":"Pt 2","key":"10.1016\/j.coi.2018.04.004_bib0635","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/bj2970351","article-title":"Structural features of the exocellular polysaccharides of Mycobacterium tuberculosis","volume":"297","author":"Lemassu","year":"1994","journal-title":"Biochem J"},{"issue":"Pt 7","key":"10.1016\/j.coi.2018.04.004_bib0640","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1099\/13500872-141-7-1609","article-title":"Molecular composition of the outermost capsular material of the tubercle bacillus","volume":"141","author":"Ortalo-Magne","year":"1995","journal-title":"Microbiology"},{"key":"10.1016\/j.coi.2018.04.004_bib0645","first-page":"187","article-title":"Manipulation of the endocytic pathway and phagocyte functions by Mycobacterium tuberculosis lipoarabinomannan","volume":"4","author":"Vergne","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.coi.2018.04.004_bib0650","doi-asserted-by":"crossref","first-page":"31417","DOI":"10.1074\/jbc.M806350200","article-title":"Identification of Mycobacterium tuberculosis clinical isolates with altered phagocytosis by human macrophages due to a truncated lipoarabinomannan","volume":"283","author":"Torrelles","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2018.04.004_bib0655","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.20051239","article-title":"The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis","volume":"202","author":"Kang","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0660","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1128\/IAI.70.5.2566-2575.2002","article-title":"Glucan is a component of the Mycobacterium tuberculosis surface that is expressed in vitro and in vivo","volume":"70","author":"Schwebach","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_bib0665","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/CVI.05550-11","article-title":"Comparative evaluation of profiles of antibodies to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIV status","volume":"19","author":"Yu","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0670","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.1073\/pnas.95.26.15688","article-title":"A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival","volume":"95","author":"Teitelbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_bib0675","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2249.2004.02593.x","article-title":"A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab\u2032) fragment prolong survival of mice infected with Mycobacterium tuberculosis","volume":"138","author":"Hamasur","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0680","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/S0264-410X(99)00124-3","article-title":"Synthesis and immunologic characterisation of Mycobacterium tuberculosis lipoarabinomannan specific oligosaccharide-protein conjugates","volume":"17","author":"Hamasur","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.04.004_bib0685","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1016\/S0264-410X(03)00274-3","article-title":"Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis","volume":"21","author":"Hamasur","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.04.004_bib0690","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/JCM.42.7.3225-3231.2004","article-title":"Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan","volume":"42","author":"Glatman-Freedman","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coi.2018.04.004_bib0695","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1086\/368096","article-title":"Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal Bacille Calmette\u2013Guerin vaccination","volume":"187","author":"Brown","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.04.004_bib0700","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1471-2334-13-276","article-title":"Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen","volume":"13","author":"Keitel","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.coi.2018.04.004_bib0705","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0022-2143(99)90204-4","article-title":"A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal Bacille Calmette\u2013Guerin vaccination","volume":"134","author":"Hoft","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.coi.2018.04.004_bib0710","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1073\/pnas.0900891106","article-title":"Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates","volume":"106","author":"Robbins","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_bib0715","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1073\/pnas.1100782108","article-title":"Oligosaccharide conjugates of Bordetella pertussis and bronchiseptica induce bactericidal antibodies, an addition to pertussis vaccine","volume":"108","author":"Kubler-Kielb","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.04.004_bib0720","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1016\/j.vaccine.2012.08.010","article-title":"A beta-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits","volume":"30","author":"Lipinski","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.04.004_bib0725","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1039\/C2CS35382B","article-title":"Designing a new antifungal glycoconjugate vaccine","volume":"42","author":"Johnson","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.coi.2018.04.004_bib0730","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.01.002","article-title":"Chemical biology approaches to designing defined carbohydrate vaccines","volume":"21","author":"Anish","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.coi.2018.04.004_bib0735","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.chembiol.2016.07.009","article-title":"Synthetic lipoteichoic acid glycans are potential vaccine candidates to protect from Clostridium difficile infections","volume":"23","author":"Broecker","year":"2016","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.coi.2018.04.004_bib0740","doi-asserted-by":"crossref","first-page":"14783","DOI":"10.1021\/jacs.7b07836","article-title":"A Streptococcus pneumoniae type 2 oligosaccharide glycoconjugate elicits opsonic antibodies and is protective in an animal model of invasive pneumococcal disease","volume":"139","author":"Emmadi","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.coi.2018.04.004_bib0745","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1128\/IAI.01847-14","article-title":"Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis","volume":"82","author":"Scott","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_bib0750","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0755","doi-asserted-by":"crossref","first-page":"10060","DOI":"10.1021\/acs.joc.5b01686","article-title":"Synthetic and immunological studies of mycobacterial lipoarabinomannan oligosaccharides and their protein conjugates","volume":"80","author":"Wang","year":"2015","journal-title":"J Org Chem"},{"key":"10.1016\/j.coi.2018.04.004_bib0760","doi-asserted-by":"crossref","first-page":"e0185945","DOI":"10.1371\/journal.pone.0185945","article-title":"A baculovirus-conjugated mimotope vaccine targeting Mycobacterium tuberculosis lipoarabinomannan","volume":"12","author":"Shin","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2018.04.004_bib0765","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/mt.2014.31","article-title":"Aptamer against mannose-capped lipoarabinomannan inhibits virulent Mycobacterium tuberculosis infection in mice and rhesus monkeys","volume":"22","author":"Pan","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2018.04.004_bib0770","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/1348-0421.12470","article-title":"A single-stranded DNA aptamer against mannose-capped lipoarabinomannan enhances anti-tuberculosis activity of macrophages through downregulation of lipid-sensing nuclear receptor peroxisome proliferator-activated receptor gamma expression","volume":"61","author":"Pan","year":"2017","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.coi.2018.04.004_bib0775","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejmech.2017.03.058","article-title":"Synthesis and immunogenicity of PG-tb1 monovalent glycoconjugate","volume":"134","author":"Meng","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coi.2018.04.004_bib0780","doi-asserted-by":"crossref","first-page":"150171","DOI":"10.1098\/rsob.150171","article-title":"Naturally produced opsonizing antibodies restrict the survival of Mycobacterium tuberculosis in human macrophages by augmenting phagosome maturation","volume":"5","author":"Kumar","year":"2015","journal-title":"Open Biol"},{"key":"10.1016\/j.coi.2018.04.004_bib0785","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.micinf.2005.12.004","article-title":"Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice","volume":"8","author":"Guirado","year":"2006","journal-title":"Microbes Infect"},{"key":"10.1016\/j.coi.2018.04.004_bib0790","doi-asserted-by":"crossref","first-page":"e1003472","DOI":"10.1371\/journal.ppat.1003472","article-title":"B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response","volume":"9","author":"Kozakiewicz","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2018.04.004_bib0795","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/IAI.00592-09","article-title":"Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model","volume":"77","author":"Lin","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2018.04.004_bib0800","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1021\/acschembio.7b00797","article-title":"Insights into interactions of mycobacteria with the host innate immune system from a novel array of synthetic mycobacterial glycans","volume":"12","author":"Zheng","year":"2017","journal-title":"ACS Chem Biol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518300402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791518300402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:43:20Z","timestamp":1760604200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791518300402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":80,"alternative-id":["S0952791518300402"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2018.04.004","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}